GlaxoSmithKline CEO: “We had to absorb a number of hits” Mon, 16 Feb 2004 Antidepressant drug safety issues are beginning to have a financial impact. Dow Jones reports: “GlaxoSmithKline PLC said its net income fell 6% in the fourth quarter, hurt by previously announced legal costs related to its anti-inflammatory…
Researcher To Be Sacked After Reporting High Rates of ADHD – BMJ Sun, 10 Apr 2005 The BMJ reports that Dr. Gretchen LeFever, a clinical psychologist and professor at Eastern Virginia Medical School, whose published reports (since 1995) have raised the alarm about a spiraling increase in elementary school children…
Member of UK Parliament Accuses Drugs Giant of ‘Voodoo Medicine’ – Scotsman Wed, 25 Feb 2004 Paul Flynn, Member of UK Parliament raised the antidepressant drug scandal in Parliament, focusing on the British drug manufacturer giant, GlaxoSmithKline (GSK). “The Seroxat [Paxil] scandal is one of gigantic proportions that affects millions…
UK: Drugs firms ‘creating ills for every pill / US ‘Bioshield’ Drug-Patent Plan Draws Fire Mon, 04 Apr 2005 Following the public revelations about the concealed safety hazards of antidepressant drugs whose risks of violence, drug dependency, and suicide, were hidden from physicians and the public, a committee of Parliament…
No legitimate physician would use the physician’s professional license to help repressive government regimes intimidate dissidents.
Pharmaceutical industry corrupt practices are in evidence again, and again, and again.
Evidence of an association between violence and widely prescribed antidepressant drugs is the focus of this Infomail.
A notice from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology.
An investigative report in Mercury News (below) focuses on Stanford University department heads, associate deans and other leaders because “these are senior people who set the tone at the medical school and are role models for junior faculty members.”
Dr. David Healy, a formidable critic of the iron grip pharmaceutical corporations wield on the practice of psychiatry as well as on psychiatry’s deficient journal reports, directs his criticism at drug regulators in an article in the current British Medical Journal (BMJ).
"Drug companies should not be allowed to evaluate their own products."
For almost two decades Eli Lilly has denied that evidence exists demonstrating that its antidepressant Prozac induced violence and suicidality.
